Abstract:Abstract Introduction: Amplification of receptor tyrosine-protein kinase erbB-2 gene (ERBB2), also known as HER2, can serve as an effective biomarker for either dual targeted therapy with trastuzumab plus lapatinib or pertuzumab plus trastuzumab in treating refractory metastatic colorectal cancer (CRC) as shown in HERACLES and MyPathway clinical trials. Next-generation sequencing (NGS) based comprehensive genomic profiling (CGP) has increasingly proven to be a valuable analysis and detection method that can make a significant impact on cancer treatment decisions. Experimental Procedure: Comprehensive genomic profiling was performed with a 450-gene next-generation sequencing (NGS) panel on both FFPE tumor and matched blood samples from a cohort of 123 Chinese colorectal cancer patients comprising 76 males and 47 females (median age was 60). All classes of genomic alterations including single-nucleotide variations, short and long insertions and deletions, copy number variations, and gene fusions were detected. Tumor mutational burden (TMB) and microsatellite instability (MSI) status were also determined by algorithms-based NGS data. Results: The most common altered genes in the 123 CRC Chinese patients were TP53 (71%), APC (70%) and KRAS (50%). 19 pts were detected by NGS as MSI-high with a median TMB value of 119 muts/Mb, which was significantly higher than in the MSS subgroup (104 pts) with a median TMB value of 10 muts/Mb (p-value was 1.5E-08). In total, 9% of the CRC pts harbored ERBB2 amplifications (11/123) by NGS panel, and it was much higher than 3-4% in Western populations. Interestingly, all 11 ERBB2 amplified cases were presented exclusively in the MSS subgroup (11/104, 11%), and were all BRAF wild-type. Five out of the 11 cases were KRAS wild-type. In addition, 9 confirmed somatic ERBB2 point mutations in the COSMIC database were detected in 7 CRC pts (7/123, 6%), including T166M, S280F, A324T, R678Q, V812I, L725S, V842I and H848Y. Four pts were MSI-high. Conclusion: CGP reveals significantly higher prevalence of both amplifications and point mutations of ERBB2/HER2 in Chinese CRC patients, compared with Western population. It may identify a subgroup of CRC patients potentially benefiting from specific targeted therapies including anti-HER2 therapies. Moreover, the highly exclusive presence of ERBB2 amplifications with MSS status could provide these patients with broader precision treatment opportunity. Citation Format: Sen Zhang, Yun Guo, Jun Jia, Weibin Shu, Hui Li, Yu Wang, Wei Zhao, Zusen Wang, Xueqing Yao, Tao Xiang, Yong Li, Ting Deng, Weifeng Wang, Kai Wang. High incidence of ERBB2 amplification associated with microsatellite stable status in Chinese colorectal cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4333.

The Absence of the ERBB4 Hotspot Mutations in Melanomas in Patients from Southern China

The Mutation Profiles of Common Oncogenes Involved in Melanoma in Southern China

Clinical significance of ERBB4 gene mutations and ERBB4 protein expression in Chinese patients with mucosal and acral melanomas

Mutations of PTEN Gene in 117 Chinese Patients with Malignant Melanoma and Their Clinical Significance

Several Mutations in the Melanocortin 4 Receptor Gene Are Associated with Obesity in Chinese Children and Adolescents

HER-2 Mutations in Chinese Lung Adenocarcinoma Patients with Negative EGFR Mutations.

Mutational Profiling of Melanomas in Patients from the Southeast Coast of China.

Identification of Anaplastic Lymphoma Kinase Break Points and Oncogenic Mutation Profiles in Acral/mucosal Melanomas

The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Epidemiological Study of HER-2 Mutations among EGFR Wild-Type Lung Adenocarcinoma Patients in China

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2

Genetic Alteration of Chinese Patients with Rectal Mucosal Melanoma.

Mutation Landscape of Chinese Melanoma Patients.

Prevalence of BRAF V600E Mutation in Chinese Melanoma Patients: Large Scale Analysis of BRAF and NRAS Mutations in a 432-Case Cohort.

BRAF mutation in Chinese melanoma patients

Melanoma in China: A Prognostic Study of 522 Cases.

Abstract 4333: High Incidence of ERBB2 Amplification Associated with Microsatellite Stable Status in Chinese Colorectal Cancer Patients

Next-generation Sequencing in Advanced Chinese Melanoma Reveals Therapeutic Targets and Prognostic Biomarkers for Immunotherapy.

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases